anti-PD-1 therapy

Overview

Anti-PD-1 therapy is a class of cancer immunotherapy in which monoclonal antibodies — nivolumab and pembrolizumab among them — block the programmed cell death protein 1 (PD-1) receptor on T cells, interrupting its engagement by the ligand PD-L1. PD-1 is an inhibitory checkpoint that normally restrains T-cell activation to limit autoimmunity, and many tumors exploit it to escape attack; blocking PD-1/PD-L1 signaling restores cytotoxic effector function in T cells that have already recognized the tumor. This is the crucial condition — the drugs release a brake rather than supply a signal, so they work only where tumor-reactive T cells are present. Anti-PD-1 belongs to the broader checkpoint inhibitor family alongside anti-PD-L1 antibodies and blockade of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and is used across many solid tumors including melanoma, hepatocellular carcinoma and cervical cancer, as well as in the tissue-agnostic setting of mismatch repair–deficient or microsatellite instability–high disease, where the indication follows a molecular feature rather than an organ.

Because the mechanism is release of a physiological restraint, the characteristic toxicities are immune-related adverse events — colitis, hepatitis, pneumonitis, dermatitis and endocrinopathies affecting the pituitary, thyroid and adrenal axes. Their management inverts the therapeutic logic, requiring corticosteroids or further immunosuppression, and endocrine damage is often permanent even when the inflammation resolves.

Response depends heavily on the tumor microenvironment. Tumors that respond tend to carry pre-existing CD8+ T-cell infiltrates and active interferon gamma signaling, while resistance is associated with T-cell exhaustion, immunosuppressive macrophage and myeloid states, cancer-associated fibroblasts including fibroblast activation protein alpha (FAP)-positive populations, and tumor-derived extracellular vesicles that propagate suppression. Alternative checkpoints such as TIGIT with its ligand CD155 can sustain inhibition even when PD-1 is blocked, and loss of interferon signaling or of antigen presentation removes the pathway the drug depends on. Current work therefore centers on converting immunologically cold tumors into responsive ones, through combinations and through mechanisms spanning CD28 costimulatory signaling that supports T-cell activation, SPP1-mediated myeloid recruitment, proprotein convertase subtilisin/kexin type 9 (PCSK9), STING-dependent innate sensing, oncolytic viruses and tumor metabolic pathways such as fatty acid uptake.

Recent Publications Summary

Recent studies have focused on anti-PD-1 therapy as both a backbone immunotherapy and a platform for combination strategies designed to overcome resistance. In hepatocellular carcinoma, multimodal sequencing of neoadjuvant nivolumab-treated tumors identified a markedly immunosuppressive tumor microenvironment in non-responders, with sparse immune infiltration, dysregulated lipogenesis, and aberrant lipid accumulation in tumor cells 42226281Jun. In the same disease context, FGFR1-driven SPP1 signaling was linked to macrophage infiltration, M2 polarization, and reduced T-cell recruitment; pharmacologic FGFR1 inhibition with BGJ398 synergized with anti-PD-1 therapy in preclinical models 41786278Mar. Another HCC study showed that intratumoral Lactobacillus johnsonii and its metabolite nicotinic acid expanded IFN-γ+PD-1+CD8+ T cells and increased effector and exhaustion markers, thereby enhancing sensitivity to PD-1 blockade 41570324Jan.

Several publications explored ways to remodel the tumor microenvironment to improve checkpoint blockade efficacy. A tumor-targeted lipid nanoparticle system delivering CD28 siRNA selectively to cancer cells reduced CD28 and PD-L1 expression, increased CD8+ T-cell and dendritic cell infiltration, and was reported to overcome anti-PD-1 resistance by reshaping the immunosuppressive milieu 42261788Jun. Similarly, ferroptosis-based therapy was shown to enhance anti-tumor immunity by promoting MHC-II-dependent antigen presentation in tumor-infiltrating macrophages, and a drug-free nano-redox strategy that induced ferroptosis synergized with anti-PD-1 therapy across preclinical models 42061406Apr. In oral squamous cell carcinoma, FAP+ fibroblasts were found to drive C1QC+ macrophage infiltration through WNT2 signaling and exacerbate T-cell exhaustion, highlighting stromal-immune circuits that may limit checkpoint response 41831519Mar. Small extracellular vesicle disruption with pH-activatable PEGylated peptides also prevented EV-mediated PD-L1 engagement with PD-1 on CD8+ T cells and improved intratumoral T-cell infiltration in vivo 42204141May.

Combination immunotherapy studies further extended anti-PD-1 therapy into multimodal regimens. In MSS/pMMR locally advanced rectal cancer, total neoadjuvant chemotherapy combined with sintilimab and IL-2 achieved a 100% R0 resection rate and a 42.4% pathological complete response rate in a phase II study 42071008May. In acral melanoma, neoadjuvant oncolytic virus plus PD-1 blockade showed sustained long-term benefit in extended follow-up, with the original phase Ib trial reporting a 77.8% pathological response rate and 81.5% 2-year relapse-free survival 42226303Jun. In metastatic NSCLC, an ongoing phase II study is evaluating alirocumab plus cemiplimab after progression on prior checkpoint inhibitor regimens, based on the rationale that PCSK9 inhibition may improve antigen presentation and overcome immunotherapy resistance 41940540Apr. Additional work in NSCLC linked LILRB2+ monocytes with improved survival and T-cell activation during ICI treatment, suggesting a predictive and mechanistic role for myeloid subsets in PD-1/PD-L1 blockade response 42069195May.

Other publications addressed biomarkers, resistance mechanisms, and safety. In dMMR colorectal cancer, an integrated multi-omics platform was used to identify tumor- and immune-related predictors of response to anti-PD-1 therapy 41995725Apr. In ovarian cancer, PAK inhibition was investigated as a partner to PD-1 blockade to enhance cytotoxic CD8+ T-cell killing and suppress invasion 41792510Mar. In esophageal cancer, a case report described multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy, underscoring the potential for rare but serious immune-related toxicities 42175425May. A review/commentary also noted unexpected effects of anti-PD-1 therapy on the blood-brain barrier, reporting that PD-1 inhibitors can induce a Wnt pathway suppressor from cytotoxic T lymphocytes that opens the barrier and may influence both brain metastasis entry and drug delivery 42063318May.

What Changes, What Holds

1. Anti-PD-1 therapy is being used as a backbone for resistance-focused combination strategies, not just as a standalone checkpoint blocker
REINFORCES These studies mostly sharpen the existing picture that response depends on the tumor microenvironment and that resistance can be overcome by altering it. The new HCC findings add specific, plausible resistance states—lipid dysregulation, suppressive myeloid signaling, and microbiome-linked immune activation—but they do not displace the baseline mechanism of PD-1/PD-L1 blockade. The practical implication is that anti-PD-1 therapy is increasingly framed as a platform for rational combinations rather than a fixed monotherapy 42226281Jun41786278Mar.

2. Remodeling stromal, myeloid, vesicular, and ferroptotic pathways may be necessary to make PD-1 blockade work in cold tumors
REINFORCES This work extends the baseline resistance model by filling in additional suppressive circuits, especially fibroblast-driven macrophage recruitment and extracellular vesicle-mediated PD-L1 engagement. It also strengthens the idea that anti-PD-1 efficacy can be improved by changing the tumor microenvironment rather than by targeting T cells alone. The ferroptosis findings are best read as a new therapeutic lever within the same framework, not a replacement for checkpoint blockade 41831519Mar42204141May.

3. Anti-PD-1 therapy is moving into multimodal regimens where its benefit depends on partner treatments and disease context
REINFORCES These studies do not alter the core account of PD-1 blockade; they show that its clinical impact can be amplified by chemotherapy, IL-2, oncolytic virus therapy, or PCSK9 inhibition. The main change is strategic: anti-PD-1 therapy is increasingly treated as a component of combination platforms, especially in tumors with known resistance. The myeloid-cell association in NSCLC also supports the baseline emphasis on immune contexture as a determinant of response 42071008May42226303Jun.

4. Response prediction and toxicity monitoring need to be integrated into anti-PD-1 use more explicitly
REINFORCES The multi-omics colorectal cancer work reinforces the baseline claim that response is biologically heterogeneous and likely shaped by both tumor-intrinsic and immune features. The endocrine case report also fits the established toxicity profile, since immune-related adverse events are already known to involve pituitary and hormonal axes. The BBB commentary adds a possible new physiologic effect, but it is still best treated as exploratory rather than practice-changing 41995725Apr42175425May.

Overview update candidates: the HCC lipid-dysregulation resistance state; FGFR1-SPP1 macrophage recruitment as a resistance mechanism; Lactobacillus johnsonii/nicotinic acid as a sensitizer to PD-1 blockade; CD28 siRNA nanoparticle remodeling of the tumor microenvironment; ferroptosis as a PD-1-sensitizing strategy; FAP+ fibroblast-driven C1QC+ macrophage infiltration and T-cell exhaustion; EV disruption preventing PD-L1 engagement; PCSK9 inhibition as a combination strategy; and the BBB-opening effect of PD-1 inhibitors.